*By Michael Teich* [Twelve percent](https://migraineresearchfoundation.org/about-migraine/migraine-facts/) of the U.S. population may suffer from chronic migraines, but many Americans don't appreciate the impact, said president of Lilly Bio-Medicines Christi Shaw. "These patients need to be treated seriously. This is a neurological disorder," Shaw said Friday in an interview on Cheddar. Eli Lilly ($LLY) just received clearance from the FDA for its latest drug, and it could change the lives of the 39 million Americans suffering from migraines, according to Shaw. The treatment, Emgality, is a monthly, self-administered injection that will help patients cut the frequency of their migraines in half, she said. Shaw said that many Americans conflate headaches and migraines, and so they often dismiss their pain. They key difference is that the symptoms of a migraine disrupt one's ability to function optimally through the day. That doesn't happen with a more commonplace headache. And a stigma contributes to the glaring statistic that only about 10 percent of those suffering from migraines take prescription drugs for prevention, Shaw said. Emgality comes with a serious price tag: $6,900 a year, or $575 a month. But Eli Lilly is offering commercially insured patients up to 12 months of the drug for free. It's among the latest efforts from the industry to offer consumers some relief from surging drug costs. Competitors Amgen ($AMGN) and Teva ($TEVA) have already unveiled new migraine treatment drugs. For full interview [click here](https://cheddar.com/videos/eli-lilly-gets-fda-approval-for-new-migraine-treatment).

Share:
More In Science
One Good Thing: All 14 Patients in Experimental Trial Saw Cancer Go Into Remission
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
A New Plant-Based Way to Quit Smoking
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
Plant-Based Way to Quit Smoking; Innovation in Stroke Therapy
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'
Load More